Posts tagged Mark Breidenbach
Roth starts Mateon at buy

Roth Capital Markets launched coverage on Mateon Therapeutics (OTCQX:MATN) with a “buy” rating and $2 price target. The stock closed at 77 cents on April 19.

Read More
Roth resumes coverage of Aduro at buy

Roth Capital Partners has reestablished estimates, a ‘buy” rating, and $17 price target for Aduro Biotech (NASDAQ:ADRO) based on a sum-of-parts, probability-adjusted net present value analysis. The stock closed at $11 on March 6. 

Read More
Roth resumes coverage of Lion Biotech at buy

Roth Capital Partners has reinitiated coverage of Lion Biotechnologies (NASDAQ:LBIO) with a “buy” rating and $14 price target. The stock closed at $7.15 on Feb. 14.

Read More
Roth resumes coverage of Viralytics at buy

Roth Capital Partners has resumed coverage of Viralytics (ASX:VLA; OTCQX:VRACY) with a “buy” rating and AUD$2 price target. The stock closed at AUD$1.05 on Jan. 30.

Read More
Roth starts Global Blood Therapeutics at buy

Roth Capital Partners initiated coverage of Global Blood Therapeutics (NASDAQ:GBT) as a “Focus Pick” with a “buy” rating and price target of $47. The stock closed at $17.45 on Monday

“In our view, Global Blood Therapeutics represents an attractive investment opportunity because its lead product, GBT440, has the potential to improve the standard of care for patients who suffer from sickle cell anemia (SCA),” writes analyst Mark Breidenbach.

Read More
Roth starts Kiadis Pharma at buy

Roth Capital Partners has initiated coverage of Kiadis Pharma (Euronext Amsterdam and Brussels: KDS) with a “buy” rating and price target of €17. The stock closed at €11.32 on Wednesday.

“We believe Kiadis Pharma warrants attention from investors because it has zeroed in on an area of high unmet medical need and is planning to take its lead program, ATIR-101, into a well-designed Phase 3 trial later this year,” writes analyst Mark Breidenbach.

Read More
Roth starts Fate Therapeutics at buy

Roth Capital Partners has launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and a target price of $8. The stock closed at $3.18 on Wednesday.

Analyst Mark Breidenbach writes that the company's lead asset, ProTmune, could address a serious unmet medical need in patients requiring hematopoietic transplants (HSCTs), and “we expect to see early clinical data by the end of 2016.”

Read More
HCW starts Kiadis Pharma at buy

H.C. Wainwright has launched coverage of Kiadis Pharma NV (NXT AM:KDS) of Amsterdam with a “buy” rating and price target of €15. The stock closed at €10 on Friday.

“We view Kiadis as an innovator in hematopoietic stem cell transplantation (HSCT) space with significant upside for the long-term investor,” writes analyst Mark Breidenbach.

Read More
HCW starts Seres Therapeutics at buy

H.C. Wainwright has initiated coverage of Seres Therapeutics (NASDAQ:MCRB) with a “buy” rating and $55 price target. The stock closed at $24.88 on Friday.

Seres is developing restorative microbial treatments that aim to improve on the clinical success of fecal microbiota transplantation (FMT), an infusion of donor fecal matter into the colon, as a viable therapeutic modality, while improving safety and removing the “ick factor” from the process.

Read More